{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"30"}]}],"title":"0 Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"20"}]}],"title":"1 Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}],"title":"2 Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"3 Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"6 Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"9 Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"groups":[{"description":"Received antimicrobial therapy alone.","id":"OG000","title":"Control Arm"},{"description":"Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.","id":"OG001","title":"Granulocyte Arm"}],"paramType":"NUMBER","populationDescription":"All randomized subjects.","reportingStatus":"POSTED","timeFrame":"Measured through Day 42","title":"Overall Incidence of Adverse Effects","type":"SECONDARY","unitOfMeasure":"participants"}